Editas Files for IPO | GenomeWeb

NEW YORK (GenomeWeb) – CRISPR/Cas9 gene editing firm Editas has filed a preliminary prospectus with US regulators for an initial public offering.

In its Form S-1, filed Monday with the US Securities and Exchange Commission, the Cambridge, Massachusetts-based company said that it plans to list on the Nasdaq Global Market under ticker symbol "EDIT."

The firm has not yet priced its shares or said how many shares it plans to offer. The IPO will be underwritten by Morgan Stanley, JP Morgan, Cowen and Company, and JMP Securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.